ArticleAnnals of laboratory medicine2023
Emergence of NDM-1-producing
Article in Annals of laboratory medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Genomic diversity ofMicrobial genomics · 2026Article
- Performance of a quality control center supporting national antimicrobial resistance surveillance.British journal of biomedical science · 2026Article
- Antimicrobial Resistance Profiles ofPolish journal of microbiology · 2025Article
- Genetic Epidemiology and Antimicrobial Susceptibilities of Carbapenem-ResistantInfection & chemotherapy · 2025Article
- Antimicrobial Resistance - The 'Real' Pandemic We Are Unaware Of, Yet Nearby.Journal of Korean medical science · 2025Review
- Analysis of intrahospital and global dissemination and resistome dynamics of NDM-1-producing ST773JAC-antimicrobial resistance · 2025Article
- Simultaneous clonal spread of NDM-1-producingIJID regions · 2024Article
- Clonal Distribution and Its Association With the Carbapenem Resistance Mechanisms of Carbapenem-Non-SusceptibleAnnals of laboratory medicine · 2024Article
- Importance of the Molecular Epidemiological Monitoring of Carbapenem-ResistantAnnals of laboratory medicine · 2024Article
- Molecular Analysis of Carbapenem and Aminoglycoside Resistance Genes in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Potentiation of Antibiotic Activity of Aztreonam against Metallo-β-Lactamase-Producing Multidrug-ResistantPharmaceutics · 2024Article
- Challenges of Carbapenem-resistantAnnals of laboratory medicine · 2024Article
- First Detection and Molecular Characterization ofMicroorganisms · 2023Article
- Antimicrobial Resistance, Genetic Lineages, and Biofilm Formation inAntibiotics (Basel, Switzerland) · 2023Article
- High incidence of carbapenemase-producingJAC-antimicrobial resistance · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Imipenemase (IMP)-6-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.